JAZZ Q2 2018 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$500M+26.9% YoY

Gross Profit

$466M93.1% margin

Operating Income

$153M30.6% margin

Net Income

$92M18.4% margin

EPS (Diluted)

$1.50

QoQ Revenue Growth

+12.6%

Cash Flow

Operating Cash Flow

$192M

Free Cash Flow

$76M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$5.3B

Total Liabilities

$2.5B

Stockholders' Equity

$2.9B

Cash & Equivalents

$485M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$500M	$394M	+26.9%
Gross Profit	$466M	$366M	+27.4%
Operating Income	$153M	$165M	-7.2%
Net Income	$92M	$106M	-12.6%

Revenue Segments

Product And Services, Product Sales

$496M50%

Xyrem

$356M36%

Erwinaze And Erwinase

$59M6%

Defitelio

$40M4%

Vyxeos

$28M3%

Prialt

$9M1%

Product And Services, Royalties And Contract Revenue

$4M0%

Other Products

$4M0%

Geographic Segments

UNITED STATES

$455M91%

Europe

$35M7%

Other Countries

$10M2%